Global leaders like Sanofi and Google, are joining forces to battle against diabetes, as the condition is becoming a major problem in many countries around the world.

Sanofi S.A. is a Paris-based multinational pharmaceutical company which won the world’s fifth-largest prescription sales in 2013. The company specializes in the research, development, manufacturing and marketing of pharmaceutical drugs. It covers seven major areas, such as: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines. They are recognized worldwide because of the company’s latest contribution towards diabetes care, with its Lantus insulin and Lyxumia, an injectable treatment for Type 2 diabetics.


“As a global leader in diabetes care, we have both an obligation and a commitment to provide integrated solutions for people living with diabetes. This initiative combines Sanofi’s strength and knowledge in diabetes with Google’s leadership in technology and analytics to create a first-of-its-kind initiative with the potential to transform diabetes care,” commented Sanofi’s CEO Olivier Brandicourt.

On the other hand, Google Life Sciences, a Google spin-off under the Alphabet umbrella, declared diabetes to be their first major disease target. Google Life Sciences CEO, Andy Conrad, said that “With new technologies emerging to provide a more continuous and real-time view of a patient’s health, we can see the promise for more proactive and effective ways to control diabetes. Together with Sanofi, we believe diabetes management can be simpler and more convenient, which may help patients achieve an improved quality of life.”

Additionally, the Joslin Diabetes Center is also excited and planning to be part of this project. “We are experiencing a worldwide pandemic of diabetes, and it’s very encouraging to see healthcare and technology innovators step up to the challenge of providing cutting edge tools and care-advancing technologies to help people with diabetes manage their disease, 24/7,”  said L. Brookes III, the Center’s CEO. Their objective, along with Google and Sanofi, is to improve patients life quality and reduce costs for people who live with the condition.

Source: NPR